50 search results for: expert insights

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

expert video

KOL Video Interview – Dr. Eric Simpson

5 min

Dermatology

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

expert video

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

3 min

Dermatology

Dr. Victoria Werth explains how diagnosing BP can pose many difficulties in patients due to the variation of symptoms and symptom severity. Dr. Werth also discusses what burden and challenges BP patients might expect as a result.

expert video

Risk of Mortality and Infections in Bullous Pemphigoid

3 min

Dermatology

Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

5 min

Dermatology

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

expert video

Navigating Atopic Dermatitis and Hand and Foot Dermatitis: Clinical Manifestations and Pathophysiology

40 min

Dermatology

Watch Drs. Simpson and Armstrong explore the clinical presentations, diagnostic challenges, and significant burdens experienced by patients with atopic dermatitis and hand and foot dermatitis, as well as the role type 2 inflammation plays in both of these diseases.

expert video

Barrier disruption in AD and the development of environmental and food allergies

2 min

Dermatology

Dr Lio discusses the role of barrier disruption in AD, and the theory behind its association with environmental and food allergen sensitization.

expert video

What Is The COPD Vicious Cycle?

3 min

Pulmonology

Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD.

Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

20 min

Dermatology

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

expert video

CSU is Unpredictable in its Course and Duration

3 min

Dermatology

Dr. Hawkes highlights how Chronic Urticaria is a mast cell centric disease with moderate levels of spontaneous remission in patients.

expert video

The Clinical Presentation of CSU is Heterogeneous

3 min

Dermatology

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region